Why the study?
To investigate the influence of allelic frequencies of PON1 Q192R, CYP2C19*2, and CYP2C19*17 genetic polymorphisms on the response to clopidogrel among Jordanian patients.
What are the allelic frequencies of PON1 Q192R, CYP2C19*2, and CYP2C19*17 genetic polymorphisms among Jordanian patients taking clopidogrel?
What are the allelic frequencies of PON1 Q192R, CYP2C19*2, and CYP2C19*17 genetic polymorphisms among Jordanian patients taking clopidogrel?
The allelic frequencies of CYP2C19 and PON1 polymorphisms in Jordanian patients on clopidogrel are consistent with Caucasian populations, highlighting a substantial proportion of intermediate metabolizers who may be at risk for inadequate platelet inhibition.
Reports allele frequencies in Jordanian patients; leaves open any influence on clopidogrel response.
Purpose: To investigate the influence of allelic frequencies of PON1 Q192R, CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the response to clopidogrel among Jordanian patients.Methods: Polymorphisms in CYP2C19 were assessed among 148 patients using PCR-RFLP assay.Results: The CYP2C19*2, CYP2C19*17, and PON1 Q192R allele frequencies were 9.8, 28.72 and 28.7 %, respectively. On the genotyping side, the frequencies of CYP2C19*1/1* and CYP2C19*1/2* were 80.4 and 19.6 %, respectively, but none of the patients had CYP2C19*2/2* genotype. The genotype frequencies CYP2C19*17 were 47.97, 46.62 and 5.41 % for wild-type C-C, heterozygote C-T, and the mutant T-T, respectively. PON1 genotype was 42.7 % for QQ, and 57.8 % for QR. None of the patients had RR genotype.Conclusion: Relative to other populations, the observed allelic frequencies are consistent with the values reported for Caucasian and Middle Eastern populations.
No takes yet. Share an insight, caveat, or question.
Rjoub et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: